Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-Oncardia
- Development stage
- Preclinical
- Lead developer
- Cell>Point LLC
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-Oncardia is an investigational **radiopharmaceutical** therapeutic being developed by CellPoint for oncology applications. It consists of **Oncardia**, a proprietary organic formulation of ethylenedicysteine-glucosamine, labeled with the beta-emitting therapeutic radioisotope **lutetium-177**. The agent is described as an **intra-nuclear radiotherapeutic compound** intended to localize to the **cell nucleus** and deliver targeted radiation that induces apoptosis of diseased cells. It is being advanced within a theranostic platform derived from research at the University of Texas M.D. Anderson Cancer Center, with reported development interest in cancers including **relapsed aggressive diffuse type B-cell lymphoma** and **lung cancer**.
- Other names
- lutetium Lu 177 Oncardia177Lu labeled OncardiaOncardia labeled with lutetium-177
Beyond the preview
Go deeper on 177Lu-Oncardia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-Oncardia.